C. Ronald Kahn

Dr. C. Ronald Kahn is a prominent professor of medicine at Harvard University and serves as the chief academic officer at Harvard’s Joslin Diabetes Center. He is well-regarded for his research in diabetes and obesity, particularly in understanding the mechanisms of insulin action and resistance. Dr. Kahn has expressed the importance of developing oral weight-loss medications, emphasizing that many patients prefer pills over injections, which aligns with the growing interest in weight-loss treatments like Eli Lilly's orforglipron, a drug recently highlighted for its efficacy in clinical trials.